Although strong preclinical data and rationale suggest a positive outcome for a SARM in SUI, the ongoing trial with a SARM for SUI is the first-in-human trial and its outcome will determine the utility of SARMs in SUI. While several other SARMs have been tested clinically for various diseases, they have not advanced beyond phase II proof-of-concept. Other companies that have previously pursued SARMs clinically are Ligand Pharmaceuticals, Merck, Glaxo, and Radius, Inc. Most of the above indicated diseases require prolonged treatment with anabolic agents, which suggests that a strong safety profile will be required. With TNBC being further sub-classified into several subsets, it may be possible that a SARM and an antagonist might provide anti-proliferative effects to distinct subsets of TNBC. This suggests a roughly 20-fold selectivity in muscle over prostate cells. Compounds with ‘favourable’ ratios are further explored and, conversely, compounds with ‘unfavorable’ ratios are discarded, even though the assay holds questionable clinically translational value beyond demonstrating any androgenic action. While differences in lifespan and the rate of biological processes between rats and humans limit comparison, it nevertheless seems that rat prostate weight changes in response to androgens are not translatable to humans. As a reproductive muscle, it is exquisitely sensitive and dependent on androgens, atrophying significantly after castration (22) and having a severalfold higher AR content than skeletal muscle (25). Their tissue selectivity, which should minimize side effects and optimize the desired action, is proposed to follow from differential tissue- or cell-specific combinatorial control of transcriptional coregulators. For completeness, it is worth noting that several AR splice variants (e.g. AR-V7) have been identified in cancers (in particular breast and prostate cancer), although most lack the ligand-binding domain (11). Much of the work relied on experimental animal data that yielded ‘anabolic-androgenic ratios’. In addition, combined expression of the AR with steroidogenic enzymes that result in increased synthesis of androgens have been shown to be extremely beneficial in breast cancer. Even before the discovery of SERMs and aromatase inhibitors, steroidal androgens such as medroxyprogesterone and fluoxymesterone were used to treat breast cancer (100). Preclinical screening of SARMs often includes determining their ability to increase levator ani muscle weight, which is used as a surrogate for anabolic activity. Androgens are important for building and maintaining skeletal muscle, and due to their anabolic effects on muscle are considered front-runners in the potential treatment of cancer cachexia and sarcopenia (43,45). Literature evidence suggests that non-genomic effects are also important for the anabolic effects of androgens and estrogens (76), whereas nuclear genomic effects are critical for the development of sexual organs. Alternatively, the SARMs and steroidal androgens utilize coactivators in anabolic tissues to promote maximal activation of the AR. "More research needs to be done to know more about SARMs’ effects and their long-term effects, but the preliminary research has raised a number of concerns," Dr. Sanyal shares. In truth, though, SARMs may be more harmful than we initially thought because they could cause widespread complications for your body. Examples of SARMs include ostarine (Enobosarm, MK 2866), andarine (S4), ligandrol (LGD-4033), LGD-3033, TT-701, RAD140 (Testolone) RAD150, and S23. Teens are targeted on social media with marketing promoting use of SARMs to increase muscle and athletic performance. The "overdose" risk is more about taking high doses for an extended time period for body building or performance enhancement. Long-term effects may include risk of heart attack or stroke, permanent liver damage, and increased risk of tendon rupture. Short-term effects include acute liver injury, increased blood pressure and heart rate, chest pain, psychological effects (such as mood swings, psychosis, irritability, anxiety), sleep disturbance, fatigue, acne, and hair loss). Most of the SARMs developed thus far are non-steroidal and have the ability to activate the AR in muscle and bone, without accompanying activation or minimal activation of the AR in prostate or seminal vesicles. Recently, a tissue-selective Farnesoid X receptor modulator was discovered with potential as a treatment for metabolic diseases (23), further increasing the number of tissue-selective nuclear receptor modulators available for therapeutic purposes. For example, the estrogens have beneficial effects in bone and brain, while having growth-promoting effects in uterus and breast (11–14). Class I is comprised of receptors for hormones such as androgens, progestins, estrogens, and corticosteroids. The androgen receptor (AR) is one of the 49 members of the steroid receptor family of ligand-activated transcription factors (1). SARMs have been proposed as treatments of choice for various diseases, including muscle-wasting, breast cancer, and osteoporosis. Although SARMs were conceived to outperform conventional androgens in both efficacy and safety, the lack of head-to-head trials makes it impossible to substantiate these claims. However autoradiography studies with radiolabeled SARMs show no preferential distribution to anabolic tissues. In tissues where coactivators are in excess (as in bone and muscle), SARMs act as agonists. Non-selective agonists such as testosterone are able to recruit coactivators when bound to AR but not corepressors and hence are agonists in all tissues. Like other type I nuclear receptors, the unliganded androgen receptor (AR) resides in the cytosol complexed with heat shock proteins (HSP). The net result is that testosterone and its metabolite together are not tissue selective. In contrast, tissue selective activation by 5α-reductase to the more active form DHT is required for significant activity in reproductive tissue. The clinical success of SERMs stimulated interest in analogous tissue selective drugs that target the AR. This occurs because the body recognizes the presence of the exogenous androgen and responds by downregulating its own production of testosterone. In one study, male rats treated with RAD-140 showed significant increases in lean body mass and muscle strength compared to a control group . Its targeted anabolic effects make it a promising candidate for future clinical applications, pending further research and regulatory approval. LGD-4033 contributes to recomposition effects, where lean muscle mass increases while fat mass decreases.
